Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Arriola Aperribay, Edurneca
- dc.contributor.author Paredes, Alfredoca
- dc.contributor.author García Gomez, R.ca
- dc.contributor.author Diz Tain, Pilarca
- dc.contributor.author Constenla, M.ca
- dc.contributor.author García Girón, C.ca
- dc.contributor.author Márquez, G.ca
- dc.contributor.author Reck, Martinca
- dc.contributor.author López Vivanco, G.ca
- dc.date.accessioned 2018-10-25T07:23:17Z
- dc.date.available 2018-10-25T07:23:17Z
- dc.date.issued 2018
- dc.description.abstract PURPOSE: The analysis of epidermal growth factor receptor (EGFR) mutations in many patients with advanced non-small-cell lung cancer (aNSCLC) has provided the opportunity for successful treatment with specific, targeted EGFR tyrosine kinase inhibitors. However, this therapeutic decision may be challenging when insufficient tumor tissue is available for EGFR mutation testing. Therefore, blood surrogate samples for EGFR mutation analysis have been suggested. METHODS: Data were collected from the Spanish cohort of patients in the large, non-interventional, diagnostic ASSESS study (NCT01785888) evaluating the utility of circulating free tumor-derived DNA from plasma for EGFR mutation testing. The incidence of EGFR mutation in Spain and the level of concordance between matched tissue/cytology and plasma samples were evaluated. RESULTS: In a cohort of 154 eligible patients, EGFR mutations were identified in 15.1 and 11.0% of tumor and plasma samples, respectively. The most commonly used EGFR mutation testing method for the tumor tissue samples was the QIAGEN Therascreen® EGFR RGQ PCR kit (52.1%). Fragment Length Analysis + PNA LNA Clamp was used for the plasma samples. The concordance rate for EGFR mutation status between the tissue/cytology and plasma samples was 88.8%; the sensitivity was 45.5%, and the specificity was 96.7%. CONCLUSIONS: The high concordance between the different DNA sources for EGFR mutation testing supports the use of plasma samples when tumor tissue is unavailable.
- dc.format.mimetype application/pdf
- dc.identifier.citation Arriola E, Paredes-Lario A, García-Gomez R, Diz-Tain P, Constenla M, García-Girón C. et al. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin Transl Oncol. 2018 Oct;20(10):1261-1267. DOI: 10.1007/s12094-018-1855-y
- dc.identifier.doi http://dx.doi.org/10.1007/s12094-018-1855-y
- dc.identifier.issn 1699-048X
- dc.identifier.uri http://hdl.handle.net/10230/35653
- dc.language.iso eng
- dc.publisher SpringerOpenca
- dc.relation.ispartof Clinical and Translational Oncology. 2018 Oct;20(10):1261-7
- dc.rights Copyright © The Author(s) 2018. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword EGFR mutation
- dc.subject.keyword Liquid biopsy
- dc.subject.keyword Non-small-cell lung cancer
- dc.subject.keyword Plasma
- dc.subject.keyword Real-world
- dc.subject.keyword ctDNA
- dc.subject.other Pulmons -- Càncer
- dc.title Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESSca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion